Exagen XGN 深 沪
等待开盘 09-11 09:30:00 美东时间
6.97
-0.340
-4.65%
华盛通- 最 高7.34
- 今 开7.21
- 成交量 19.75万股
- 最 低 6.83
- 昨 收 7.31
- 总市值 1.69亿
- 52周最高 12.23
- 市盈率 静 --
- 换手率 0.82%
- 52周最低 2.59
- 委 比 -97.04%
- 总股本 2422.53万
- 历史最高 29.858
- 量 比 1.01
- 振 幅 6.98%
- 历史最低 1.3003
- 每 手 1
- 风险率 2.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
BTIG Maintains Buy on Exagen, Raises Price Target to $9
BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.
08-05 20:08
美股牛股 | 绩优股齐升！Palantir大涨逾29%，Q2营收强劲增长并上调全年指引；Wayfair飙升30%，Corvex涨逾27%
绩优股齐升！Palantir大涨逾29%，Q2营收暴增93%并上调全年指引；Wayfair飙升30%，Q2业绩全面超预期；Corvex涨逾27%，斩获AI巨头Blackwell供应协议>>
08-05 19:24
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Exagen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
08-04 22:21
北美市场早间简报：科技股反弹持续，股指期货走高
Suncor Energy 第二季度财报 经济指标（美东时间）： 08：30 6月国际商品贸易 09：30 7月加拿大制造业PMI 值得关注...
08-04 20:20
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est
Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.
08-04 20:01
中东战火催化出油气巨头强劲业绩，埃克森美孚利润创俄乌冲突以来新高
尽管原油价格飙升，燃油生产利润率不断扩大，但随着美伊冲突进入第六个月，埃克森美孚控股公司仍未能达到盈利预期。该公司总利润为 147 亿美元，是自 2022 年俄罗斯入侵乌克兰扰乱全球市场以来最高的，但经调整后的第二季度收益比平均预期低 2 美分。
07-31 20:50
Exagen Inc. to Participate in Upcoming Investor Conference
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune diagnostics, announced its participation in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, in Boston, MA. The event will feature a Fireside Chat at 8:30am ET, available live and archived on Exagen’s Investor Relations website. Exagen, based in California, focuses on improving autoimmune disease management through innovative testing solutions like AVISE® CTD, aidi...
07-28 13:00
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
